During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, about what factors should be considered when sequencing therapy in relapsed/refractory (R/R) follicular lymphoma.